Co-Diagnostics

Co-Diagnostics Stock-Based Compensation

The Stock-Based Compensation (SBC) of Co-Diagnostics (CODX) as of Nov 20, 2026 is 2.25 M USD. In the previous year, Stock-Based Compensation (SBC) was 5.43 M USD — a change of -58.64% (lower).

Stock-Based Compensation

2.25 MUSD

YoY

-58.64%

Last updated:

Stock-Based Compensation (SBC) of Co-Diagnostics is 2025 2.25 M USD. Stock-Based Compensation (SBC) of Co-Diagnostics was 2024 5.43 M USD. It decreases by -58.64% lower compared to the previous year.

The Co-Diagnostics Stock-Based Compensation history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Stock-Based Compensation
Date
Stock-Based Compensation
Jan 1, 2018
1.33 M USD
Jan 1, 2019
1.09 M USD
Jan 1, 2020
2.74 M USD
Jan 1, 2021
5.51 M USD
Jan 1, 2022
7.54 M USD
Jan 1, 2023
8.34 M USD
Jan 1, 2024
5.43 M USD
Jan 1, 2025
2.25 M USD
The Co-Diagnostics Stock-Based Compensation history
YEARStock-Based CompensationYoY
2.25 MUSD-58.64%
5.43 MUSD-34.81%
8.34 MUSD+10.52%
7.54 MUSD+36.92%
5.51 MUSD+101.22%
2.74 MUSD+151.57%
1.09 MUSD-18.31%
1.33 MUSD-34.49%
2.03 MUSD+2,823.82%
69,565.00USD+52.90%
45,498.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Co-Diagnostics Stock analysis

What does Co-Diagnostics do? Co-Diagnostics, Inc. develops and sells diagnostic tests using proprietary reagents and a test design system for diseases and pathogens including tuberculosis, drug-resistant tuberculosis, hepatitis B and C, malaria, dengue, HIV, and Zika virus. The company also markets self-contained lab systems (MDx devices) from other manufacturers. Its products are sold to laboratories and healthcare providers for molecular testing of organisms and genetic diseases, automating complex procedures in test development and administration. The firm generates revenue through the sale of diagnostic reagents, validated tests, and MDx devices. The company's diagnostic technology focuses on nucleic acid detection and analysis, enabling molecular testing for various pathogens and genetic conditions. Its proprietary system allows for the design and validation of tests in-house, which are then marketed to healthcare institutions. Revenue streams include reagent sales, test kits, and equipment from partner manufacturers. Co-Diagnostics, Inc. targets laboratories and healthcare providers as key customers for its diagnostic solutions. The firm's products are designed to streamline molecular testing processes, reducing the complexity of traditional methods. This approach supports the company's revenue model based on direct sales of its proprietary tests and complementary equipment. Co-Diagnostics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Co-Diagnostics stock

Stock-Based Compensation (SBC) of Co-Diagnostics is 2.25 M USD in 2025.

Stock-Based Compensation (SBC) of Co-Diagnostics changed from 5.43 M USD to 2.25 M USD, representing a -58.64% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Stock-Based Compensation (SBC) Co-Diagnostics since 2006 – with annual values, charts, and detailed analysis.

Stock-based compensation is a non-cash expense representing equity awards to employees. High SBC can dilute existing shareholders and inflate reported cash flow.

Stock-Based Compensation (SBC)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Stock-Based Compensation (SBC)'s Co-Diagnostics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Co-Diagnostics

All Key Metrics — Co-Diagnostics